Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00137371|
Recruitment Status : Completed
First Posted : August 29, 2005
Last Update Posted : December 10, 2007
|Condition or disease||Intervention/treatment||Phase|
|Atrophic Vaginitis Atrophy Vaginitis||Drug: PVC (daily for 21 days, 7 days off) Drug: PVC (twice weekly)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||480 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy and Safety of 2 Low-Dose Regimens of Conjugated Estrogen Cream Administered Vaginally in Postmenopausal Women With Atrophic Vaginitis|
|Study Start Date :||August 2005|
|Study Completion Date :||September 2007|
- To evaluate the efficacy of 2 low dose regimens of conjugated estrogen in the treatment of atrophic vaginitis from baseline to 12 weeks.
- To evaluate change from baseline in the percentage of superficial cells, symptom relief, the effect of both regimens on endometrial stimulation and genital health.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00137371
Show 49 Study Locations
|Principal Investigator:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|